Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic dyslipidaemia.

P N Durrington1

  • 1Department of Medicine, University of Manchester, Manchester Royal Infirmary, UK.

Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism
|April 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national hospital records.

Atherosclerosis·2025
Same author

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Atherosclerosis·2018
Same author

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

European journal of preventive cardiology·2011
Same author

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).

Diabetic medicine : a journal of the British Diabetic Association·2010
Same author

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.

Atherosclerosis·2010
Same author

Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations.

Atherosclerosis·2009
Same journal

Inhibin B in the assessment of seminiferous tubular function.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Post-Chernobyl thyroid carcinoma in children.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Surgical approach to thyroid nodules and cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Diagnosis and treatment of medullary thyroid cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Management of undifferentiated thyroid cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Papillary and follicular thyroid carcinoma.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
See all related articles

Diabetes significantly increases coronary heart disease risk. Managing dyslipidemia with statins is crucial, with fibrates useful for extreme hypertriglyceridemia in diabetic patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Diabetes mellitus (Type 1 and Type 2) elevates the risk of coronary heart disease (CHD) and atherosclerosis.
  • Diabetic dyslipidemia is characterized by hypertriglyceridemia and low high-density lipoprotein (HDL) cholesterol, worsening with nephropathy.
  • Serum cholesterol risk for CHD is higher in diabetics, but influenced by population-level cholesterol averages.

Purpose of the Study:

  • To review the impact of dyslipidemia on cardiovascular risk in diabetes.
  • To evaluate the role of lipid-lowering therapies, specifically statins and fibrates, in managing diabetic dyslipidemia and preventing CHD.

Main Methods:

  • Review of existing clinical trial data and observational studies on lipid profiles in diabetic patients.

Related Experiment Videos

  • Analysis of the mechanisms by which hypertriglyceridemia contributes to CHD risk in diabetes.
  • Assessment of the efficacy of statins and fibrates in lipid modification and CHD prevention.

    • Main Results:

    • Statins demonstrate strong evidence for decreasing CHD risk, particularly in secondary prevention.
    • Hypertriglyceridemia exacerbates CHD risk in diabetes through effects on low-density lipoprotein (LDL) particle size and oxidation.
    • Both statins and fibrates can reduce cholesteryl ester transfer, a key factor in atherogenesis.

    Conclusions:

    • Statins are recommended as a standard treatment in routine diabetic care for CHD risk reduction.
    • Fibrates have a more specific role in managing extreme hypertriglyceridemia in diabetic patients.
    • Further research on fibrates with clinical endpoints is needed to fully define their role in CHD prevention in diabetes.